A Phase 1 interventional study of MSC1936369B (pimasertib) and SAR245409 (PI3K and mTOR inhibitor) in Locally Advanced Solid Tumor, Metastatic Solid Tumor and Breast Cancer, sponsored by EMD Serono. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2017-03-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Merck KGaA, Darmstadt, Germany.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 1, and was the 13th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →None of the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Neoplasm Metastasis, anywhere →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 82 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 5 · Phase 3 1
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 141 across the 17 interventional studies, 438 across the 4 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumors. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject with advanced solid tumors for which there is no approved therapy:
Subjects enrolled in disease specific expansion cohorts must fulfill all the inclusion/exclusion criteria listed above with the following restriction to the Inclusion Criterion number 1:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MSC1936369B (pimasertib) · Drug: SAR245409 (PI3K and mTOR inhibitor)
Drug: MSC1936369B (pimasertib) · Drug: SAR245409 (PI3K and mTOR inhibitor)
MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
Also known as: Pimasertib
Drug page: XL765
SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
Also known as: PI3K and mTOR inhibitor
MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
Also known as: pimasertib
Drug page: XL765
SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
Also known as: PI3K and mTOR inhibitor
Number of Subjects With Dose Limiting Toxicities (DLT)
DLT was defined as any of the following toxicities experienced during the first cycle of treatment at any dose level (DL) and judged not to be related to the underlying disease or any concomitant medication by the Investigator and/or the Sponsor: A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation (DE) would have exposed subjects to unacceptable risk. Any Grade greater than or equal to (\>=) 3 non-hematological toxicity, except for: Grade 3 diarrhea, nausea and vomiting with a duration less than or equal to (\<=) 48 hours despite adequate supportive care and Alopecia. Grade 4 neutropenia of \> 5 days duration or febrile neutropenia. Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia. Any treatment interruption \> 2 weeks due to AEs not related to the underlying disease or concomitant medication at any dose level and any severe, life-threatening impairing daily functions complication or abnormality.
Time frame: Day 1 up to Day 16 in cycle 1
Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as those AEs that started between first dose of study drug and up to 30 days after last dose.
Time frame: Baseline up to 30 Days after last dose; assessed up to 4 years
Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)
Area under the concentration-time curve from time 0 to the last quantifiable concentration.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1
Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz).
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts
Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Half-Life (t1/2) of MSC1936369B (Pimasertib)
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)
The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15
Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau per Day 1 dosing interval AUCtau.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15
Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax/Day 1 Cmax.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Maximum Observed Plasma Concentration (Cmax) for SAR245409
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409
The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409
Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour\*nanogram per milliliter (hr\*ng/mL).
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1
Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts
Apparent Terminal Half-Life (t1/2) of SAR245409
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Total Body Clearance (CL/f) of SAR245409
The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the dose with area under the plasma concentration time curve from time zero to infinity (AUC 0-inf)=Dose/AUC 0-inf.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15
Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau divided by Day 1 dosing interval AUCtau.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15
Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax divided by Day 1 Cmax.
Time frame: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts
pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)
pS6 Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.
Time frame: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); Cycle 1 Day 1 (C1D1) and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)
pERK Concentrations in PBMCs
pERK Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.
Time frame: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); C1D1 and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)
Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)
CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From the date of randomisation every 6 weeks up to assessed up to 4 years
First subject (informed consent): May 2011. Study completion date: Apr 2015. A total of 192 subjects were screened and 146 subjects entered the trial and received the investigational medicinal product (IMP).
| Milestone | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 | 19 | 14 | 3 | 3 | 4 | 26 | 24 | 18 | 15 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 | 19 | 14 | 3 | 3 | 4 | 26 | 24 | 18 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DLT was defined as any of the following toxicities experienced during the first cycle of treatment at any dose level (DL) and judged not to be related to the underlying disease or any concomitant medication by the Investigator and/or the Sponsor: A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation (DE) would have exposed subjects to unacceptable risk. Any Grade greater than or equal to (\>=) 3 non-hematological toxicity, except for: Grade 3 diarrhea, nausea and vomiting with a duration less than or equal to (\<=) 48 hours despite adequate supportive care and Alopecia. Grade 4 neutropenia of \> 5 days duration or febrile neutropenia. Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia. Any treatment interruption \> 2 weeks due to AEs not related to the underlying disease or concomitant medication at any dose level and any severe, life-threatening impairing daily functions complication or abnormality.
| subjects | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Dose Limiting Toxicities (DLT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as those AEs that started between first dose of study drug and up to 30 days after last dose.
| subjects | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs) | 3 | 3 | 3 | 4 | 4 | 3 | 19 | 14 | 3 | 3 | 4 | 26 | 24 | 18 | 15 |
| nanogram/millilitre (ng/mL) | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 10, 26, 13, 4, 3, 25, 23, 18, 15) | 86.06 (51.31 to 144.3) | 188.2 (138.5 to 255.9) | 246.1 (191.8 to 315.6) | 406.9 (284.6 to 581.7) | 83.72 (18.05 to 388.3) | 232.5 (190.9 to 283.2) | 323.1 (253.9 to 411.1) | 295.4 (240.9 to 362.2) | 245.6 (198.5 to 304.0) | 234.0 (182.6 to 299.8) |
| Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 13, 10) | 131.3 (85.13 to 202.6) | 212.8 (178.9 to 253.1) | 234.2 (166.2 to 330.1) | 516.4 (375.0 to 711.0) | 143.1 (22.82 to 897.8) | NA (NA to NA) | 320.5 (286.2 to 358.9) | 327.6 (248.5 to 431.9) | 307.7 (205.0 to 461.8) | 338.9 (281.0 to 408.8) |
| hour | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n= 6, 10, 25, 13, 4, 3, 25, 23, 18, 15 ) | 1.750 (0.50 to 2.08) | 0.765 (0.50 to 2.15) | 2.020 (0.50 to 8.05) | 1.500 (0.50 to 3.00) | 1.485 (0.50 to 2.08) | 1.550 (0.50 to 2.07) | 1.500 (0.50 to 7.90) | 1.520 (0.50 to 7.85) | 1.490 (0.50 to 4.20) | 1.050 (0.45 to 4.00) |
| Day 15 (n= 6, 9, 15, 9, 3, 1, 16, 17, 13, 10) | 1.275 (0.50 to 3.07) | 1.000 (1.00 to 1.63) | 2.000 (1.00 to 7.95) | 1.550 (1.00 to 2.00) | 2.000 (1.50 to 4.17) | NA (NA to NA) | 1.505 (0.53 to 3.00) | 1.530 (1.00 to 4.00) | 1.500 (0.50 to 8.00) | 1.030 (0.48 to 3.83) |
Area under the concentration-time curve from time 0 to the last quantifiable concentration.
| hour*nanogram per millilitre (hr*ng/mL) | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 10, 25, 13, 4, 3, 25, 23, 18, 15) | 426.8 (306.2 to 594.9) | 734.4 (586.1 to 920.3) | 1547 (1238 to 1934) | 2116 (1664 to 2692) | 326.1 (110.9 to 958.7) | 1252 (1100 to 1425) | 1781 (1404 to 2260) | 1754 (1480 to 2078) | 1709 (1361 to 2146) | 1093 (871.5 to 1371) |
| Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 10, 13) | 625.3 (405.7 to 963.9) | 902.0 (747.6 to 1088) | 1617 (1170 to 2236) | 2552 (2185 to 2980) | 773.1 (201.0 to 2974) | NA (NA to NA) | 2136 (1713 to 2663) | 1889 (1540 to 2318) | 1988 (1487 to 2658) | 1506 (1141 to 1988) |
Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz).
| hr*ng/mL | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1 | 451.6 (319.8 to 637.8) | 770.9 (599.9 to 990.6) | 1607 (1237 to 2087) | 2202 (1716 to 2826) | 503.1 (153.1 to 1654) | — | 1869 (1451 to 2407) | 1830 (1518 to 2207) | 1857 (1414 to 2437) | 1113 (858.9 to 1442) |
| hr*ng/mL | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n= 6, 10, 26, 13, 3, 3, 24, 23, 17,13) | 426.8 (306.2 to 594.9) | 742.1 (602.0 to 914.7) | 1547 (1238 to 1934) | 2116 (1664 to 2692) | 354.9 (48.21 to 2613) | 1252 (1100 to 1425) | 1882 (1513 to 2341) | 1754 (1480 to 2078) | 1772 (1409 to 2227) | 1093 (871.5 to 1371) |
| Day 15 (n=6, 9, 15, 9, 3, 0, 16, 17, 10, 13) | 650.4 (440.1 to 961.2) | 902.0 (747.6 to 1088) | 1617 (1170 to 2236) | 2552 (2185 to 2980) | 773.1 (201.0 to 2974) | NA (NA to NA) | 2136 (1713 to 2663) | 1889 (1540 to 2318) | 1988 (1487 to 2658) | 1506 (1141 to 1988) |
| hour | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 9, 23, 13, 4, 3, 22, 22, 15, 13) | 6.250 (5.03 to 7.16) | 4.670 (1.85 to 5.79) | 4.840 (3.23 to 9.99) | 4.800 (3.49 to 7.62) | 3.320 (2.60 to 4.72) | 4.640 (4.25 to 4.74) | 4.840 (2.46 to 8.41) | 4.370 (3.71 to 8.26) | 4.770 (3.51 to 12.8) | 4.240 (3.32 to 4.84) |
| Day 15 (n=6, 9, 14, 9, 2, 1, 16, 16, 9, 12) | 5.855 (2.93 to 7.88) | 5.410 (3.90 to 10.8) | 6.755 (4.61 to 14.3) | 5.590 (3.97 to 14.1) | NA (NA to NA) | NA (NA to NA) | 5.210 (3.25 to 12.8) | 5.250 (4.33 to 8.65) | 5.210 (4.80 to 6.94) | 4.325 (3.40 to 5.96) |
The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf.
| litre per hour (L/hr) | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 10, 26, 13, 3, 0, 22, 22, 14, 13) | 33.22 (23.52 to 46.92) | 38.90 (30.26 to 50.00) | 37.99 (29.33 to 49.22) | 40.88 (31.85 to 52.47) | 89.49 (27.14 to 295.1) | NA (NA to NA) | 32.12 (24.95 to 41.36) | 32.75 (27.16 to 39.50) | 30.75 (23.41 to 40.41) | 53.94 (41.61 to 69.62) |
| Day 15 (n=6, 9, 15, 9, 3, 1, 16, 17, 10, 13) | 23.06 (15.59 to 34.10) | 33.30 (27.63 to 40.13) | 37.11 (26.82 to 51.33) | 35.28 (30.19 to 41.23) | 58.22 (15.03 to 225.6) | NA (NA to NA) | 28.11 (22.54 to 35.07) | 31.73 (25.85 to 38.94) | 30.20 (22.59 to 40.38) | 39.81 (30.17 to 52.52) |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.
| liter | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 9, 23, 13, 3, 0, 22, 22, 14, 13) | 294.3 (218.5 to 396.4) | 240.2 (202.5 to 284.9) | 282.8 (227.7 to 351.4) | 283.0 (224.0 to 357.6) | 394.1 (146.9 to 1058) | — | 223.8 (182.7 to 274.3) | 226.9 (193.9 to 265.4) | 216.2 (174.6 to 267.8) | 322.0 (251.5 to 412.3) |
| Day 15 (n=6, 9, 13, 9, 0, 0, 16, 16, 9, 12) | 188.7 (133.4 to 266.9) | 261.8 (187.9 to 364.8) | 396.4 (276.9 to 567.3) | 302.4 (223.1 to 409.7) | NA (NA to NA) | — | 226.3 (189.7 to 270.1) | 250.9 (214.2 to 293.9) | 230.6 (169.0 to 314.6) | 273.8 (213.8 to 350.7) |
Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau per Day 1 dosing interval AUCtau.
| ratio | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15 | 1.523 (1.295 to 1.792) | 1.269 (1.107 to 1.455) | 1.174 (0.9326 to 1.479) | 1.364 (1.133 to 1.642) | 2.176 (0.1184 to 39.99) | NA (NA to NA) | 1.368 (1.044 to 1.792) | 1.155 (1.004 to 1.330) | 1.245 (0.9538 to 1.625) | 1.283 (1.104 to 1.490) |
Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax/Day 1 Cmax.
| ratio | Pimasertib (MSC1936369B) 15mg | Pimasertib (MSC1936369B) 30mg | Pimasertib (MSC1936369B) 60mg | Pimasertib (MSC1936369B) 90mg | Pimasertib (MSC1936369B) 45mg Twice Daily | Pimasertib (MSC1936369B) 60mg Twice Daily | TNBC: Pimasertib 60mg Once Daily | NSCLC: Pimasertib 60mg Once Daily | CRC: Pimasertib 60mg Once Daily | MEL: Pimasertib 60mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15 | 1.525 (1.002 to 2.322) | 1.066 (0.7442 to 1.527) | 1.106 (0.7904 to 1.546) | 1.308 (0.7537 to 2.268) | 1.467 (0.02541 to 84.67) | NA (NA to NA) | 1.203 (0.9074 to 1.595) | 1.059 (0.8875 to 1.263) | 1.247 (0.8719 to 1.784) | 1.393 (1.091 to 1.780) |
| nanogram per millilitre (ng/mL) | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15) | 192.0 (115.6 to 316.3) | 295.7 (189.0 to 462.6) | 256.9 (203.5 to 324.3) | 224.5 (99.72 to 505.2) | 130.2 (20.76 to 816.5) | 64.22 (19.25 to 214.2) | 323.6 (258.4 to 405.2) | 240.6 (164.6 to 351.6) | 239.6 (158.8 to 361.4) | 212.5 (129.3 to 349.4) |
| Day 15 (n=6, 6, 25, 1, 1, 3, 17, 17, 10, 13) | 199.8 (114.4 to 349.1) | 224.1 (132.7 to 378.4) | 222.9 (143.7 to 345.7) | NA (NA to NA) | NA (NA to NA) | 117.2 (7.210 to 1907) | 326.0 (256.4 to 414.6) | 235.5 (144.6 to 383.3) | 178.9 (82.31 to 389.0) | 226.6 (143.9 to 356.7) |
The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated.
| hours | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15) | 1.510 (0.53 to 2.08) | 1.150 (0.50 to 4.10) | 1.500 (0.50 to 23.80) | 1.500 (1.00 to 8.00) | 2.050 (1.50 to 2.07) | 1.540 (0.50 to 4.00) | 1.500 (0.52 to 8.03) | 2.000 (0.50 to 4.17) | 2.000 (0.43 to 8.05) | 1.500 (0.95 to 4.00) |
| Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13) | 1.265 (1.00 to 2.00) | 1.750 (0.53 to 3.00) | 1.970 (1.00 to 8.13) | NA (NA to NA) | NA (NA to NA) | 1.550 (1.50 to 8.00) | 2.030 (0.52 to 7.98) | 1.530 (0.92 to 8.00) | 1.750 (0.50 to 8.00) | 1.050 (0.50 to 3.97) |
Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour\*nanogram per milliliter (hr\*ng/mL).
| hr*ng/mL | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15) | 683.6 (248.9 to 1878) | 1248 (760.1 to 2050) | 1566 (1162 to 2111) | 3032 (1425 to 6454) | 634.0 (111.8 to 3595) | 226.2 (82.99 to 616.7) | 1976 (1449 to 2693) | 1408 (962.5 to 2059) | 1479 (824.6 to 2653) | 854.9 (505.0 to 1447) |
| Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13) | 861.0 (371.5 to 1995) | 1125 (558.3 to 2266) | 1334 (895.8 to 1986) | NA (NA to NA) | NA (NA to NA) | 537.5 (56.10 to 5150) | 2232 (1512 to 3297) | 1437 (922.1 to 2239) | 1365 (543.4 to 3431) | 968.8 (554.8 to 1692) |
| hr*ng/mL | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 11, 36, 3, 3, 3, 24, 23, 17, 15) | 746.9 (275.5 to 2024) | 1265 (784.5 to 2041) | 1601 (1195 to 2145) | 3032 (1425 to 6454) | 634.0 (111.8 to 3595) | 298.6 (120.4 to 740.6) | 2115 (1535 to 2915) | 1480 (1026 to 2137) | 1542 (851.5 to 2792) | 948.4 (601.8 to 1495) |
| Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13) | 887.9 (397.9 to 1981) | 1168 (611.5 to 2232) | 1362 (918.9 to 2018) | NA (NA to NA) | NA (NA to NA) | 537.5 (56.10 to 5150) | 2390 (1696 to 3368) | 1437 (922.1 to 2239) | 1365 (543.4 to 3431) | 1074 (636.9 to 1811) |
Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.
| hr*ng/mL | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1 | 716.5 (181.8 to 2823) | 1165 (648.3 to 2093) | 1504 (1113 to 2034) | NA (NA to NA) | NA (NA to NA) | 331.2 (151.5 to 724.1) | 1974 (1408 to 2768) | 1445 (1019 to 2049) | 1261 (579.4 to 2743) | 1142 (750.4 to 1739) |
| hour | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=6, 9, 31, 2, 2, 3, 20, 19, 13, 14) | 3.055 (1.78 to 7.57) | 3.300 (1.45 to 8.94) | 3.390 (0.964 to 9.28) | NA (NA to NA) | NA (NA to NA) | 3.310 (2.47 to 3.37) | 3.755 (1.32 to 7.59) | 3.300 (2.54 to 27.9) | 4.070 (2.14 to 9.02) | 3.120 (1.32 to 6.03) |
| Day 15 (n=6, 8, 22, 1, 1, 2, 10, 15, 8, 10) | 3.700 (2.07 to 5.60) | 4.570 (1.81 to 6.49) | 4.560 (2.37 to 35.2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.840 (1.48 to 5.63) | 4.050 (2.74 to 7.87) | 6.170 (3.43 to 11.8) | 3.065 (1.79 to 5.37) |
The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the dose with area under the plasma concentration time curve from time zero to infinity (AUC 0-inf)=Dose/AUC 0-inf.
| litre per hour | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12) | 41.80 (10.62 to 164.5) | 42.93 (23.89 to 77.16) | 46.54 (34.42 to 62.94) | NA (NA to NA) | NA (NA to NA) | 151.4 (69.37 to 330.4) | 35.43 (25.26 to 49.69) | 48.40 (34.12 to 68.64) | 55.51 (25.52 to 120.7) | 61.29 (40.26 to 93.30) |
| Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13) | 33.78 (15.16 to 75.26) | 42.81 (22.39 to 81.85) | 51.38 (34.68 to 76.13) | NA (NA to NA) | NA (NA to NA) | 92.90 (9.667 to 892.8) | 29.28 (20.78 to 41.26) | 48.69 (31.25 to 75.88) | 51.24 (20.38 to 128.8) | 65.16 (38.64 to 109.9) |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.
| litre | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12) | 174.8 (71.24 to 429.0) | 223.4 (116.2 to 429.6) | 238.5 (179.0 to 317.8) | NA (NA to NA) | NA (NA to NA) | 658.0 (211.9 to 2044) | 175.2 (123.9 to 247.9) | 251.4 (158.4 to 398.9) | 353.6 (177.1 to 705.8) | 270.3 (175.6 to 416.0) |
| Day 15 (n=6, 8, 25, 1, 1, 2, 17, 17, 10, 13 ) | 165.7 (99.48 to 276.1) | 257.2 (156.7 to 422.1) | 355.9 (212.5 to 596.2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 132.8 (96.16 to 183.4) | 247.1 (149.4 to 410.7) | 475.9 (128.0 to 1769) | 293.4 (141.6 to 607.7) |
Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau divided by Day 1 dosing interval AUCtau.
| ratio | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15 | 1.189 (0.6118 to 2.311) | 1.004 (0.4637 to 2.175) | 0.9450 (0.6749 to 1.323) | NA (NA to NA) | NA (NA to NA) | 1.800 (0.1724 to 18.79) | 1.256 (0.9407 to 1.676) | 0.9887 (0.7202 to 1.357) | 1.187 (0.7614 to 1.850) | 1.022 (0.6346 to 1.645) |
Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax divided by Day 1 Cmax.
| Ratio | SAR245409 30mg | SAR245409 50mg | SAR245409 70mg | SAR245409 90mg | SAR245409 30mg Twice Daily | SAR245409 50mg Twice Daily | TNBC: SAR245409 70mg Once Daily | NSCLC: SAR245409 70mg Once Daily | CRC: SAR245409 70mg Once Daily | MEL: SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15 | 1.041 (0.6293 to 1.722) | 0.8133 (0.3484 to 1.898) | 0.8962 (0.6151 to 1.306) | NA (NA to NA) | NA (NA to NA) | 1.336 (0.03347 to 53.32) | 1.070 (0.8319 to 1.375) | 0.8950 (0.6951 to 1.152) | 0.9611 (0.6441 to 1.434) | 0.9942 (0.5447 to 1.815) |
pS6 Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.
| fluorescence intensity | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|
| DDI Day 1: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1) | 61.02 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 33.78 ± NA |
| DDI Day 1: 2hr post-dose (n= 1,0,0,0,0,0,1) | 36.15 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 29.84 ± NA |
| DDI Day 1: 4hr post-dose (n= 1,0,0,0,0,0,1) | 89.14 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 30.28 ± NA |
| DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1) | 54.54 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 44.88 ± NA |
| DDI Day 1: 24hr post-dose (n= 1,0,0,0,0,0,0) | 88.80 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| DDI Day 2: 24hr post-dose (n= 0,0,0,0,0,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 28.86 ± NA |
| DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1) | 57.51 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 14.90 ± NA |
| DDI Day 3: 2hr post-dose (n= 1,0,0,0,0,0,1) | 55.93 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 34.06 ± NA |
| DDI Day 3: 4hr post-dose (n= 1,0,0,0,0,0,1) | 36.76 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1.03 ± NA |
| DDI: Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1) | 1.08 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 40.40 ± NA |
| DDI:Day 3: 24hr post-dose (n= 1,0,0,0,0,0,0) | 87.60 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| DDI Day 4: 24hr post-dose (n= 0,0,0,0,0,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1.04 ± NA |
| C1D1: Pre dose (n= 1,1,1,1,1,1,1) | 51.32 ± NA | 83.52 ± NA | 96.98 ± NA | 47.09 ± NA | 50.17 ± NA | 4.18 ± NA | 36.03 ± NA |
| C1D1: 2hr postdose (n= 1,1,1,1,1,1,1) | 31.08 ± NA | 24.48 ± NA | 56.41 ± NA | 23.89 ± NA | 5.72 ± NA | 0.92 ± NA | 1.04 ± NA |
| C1D1: 4hr postdose (n= 1,1,1,1,1,1,1) | 25.71 ± NA | 46.95 ± NA | 50.11 ± NA | 29.85 ± NA | 18.21 ± NA | 0.72 ± NA | 0.94 ± NA |
| C1D1: 8hr postdose (n= 1,1,1,1,1,1,1) | 3.02 ± NA | 1.28 ± NA | 84.57 ± NA | 19.75 ± NA | 6.21 ± NA | 1.18 ± NA | 0.96 ± NA |
| C1D1: 24hr postdose(n= 1,1,1,1,0,0,0) | 46.16 ± NA | 72.14 ± NA | 74.15 ± NA | 53.47 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D2: 24hr postdose (n= 0,0,0,0,1,1,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 24.66 ± NA | 1.61 ± NA | 1.00 ± NA |
| C1D15: pre-dose (n= 1,1,1,1,1,0,1) | 43.48 ± NA | 81.29 ± NA | 67.69 ± NA | 1.20 ± NA | 33.43 ± NA | NA ± NA | 0.98 ± NA |
| C1D15: 2hr postdose (n= 1,1,1,1,1,0,1) | 26.41 ± NA | 43.70 ± NA | 48.23 ± NA | 15.02 ± NA | 21.11 ± NA | NA ± NA | 1.06 ± NA |
| C1D15: 4hr postdose (n= 1,1,1,1,1,0,1) | 41.34 ± NA | 53.37 ± NA | 92.67 ± NA | 0.96 ± NA | 19.68 ± NA | NA ± NA | 1.03 ± NA |
| C1D15: 8hr postdose (n= 1,1,1,1,1,0,1) | 0.53 ± NA | 45.97 ± NA | 77.62 ± NA | 36.06 ± NA | 30.08 ± NA | NA ± NA | 0.88 ± NA |
| C1D15: 24hr postdose (n= 1,1,1,1,0,0,0) | 69.93 ± NA | 0.76 ± NA | 114.39 ± NA | 70.46 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D16: 24hr postdose (n= 0,0,0,0,1,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 24.36 ± NA | NA ± NA | 0.98 ± NA |
| C1D19: pre-dose (n= 1,1,1,1,1,0,1) | 68.48 ± NA | 90.02 ± NA | 125.77 ± NA | 82.06 ± NA | 30.58 ± NA | NA ± NA | 49.62 ± NA |
| C1D19: 2hr postdose (n= 1,0,0,0,0,0,0) | 4.34 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
pERK Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for "Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily", "Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily", "Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily" and "Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily" reporting arms.
| fluorescence intensity | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|
| DDI Day 1: Predose (n= 1, 0, 0, 0, 0, 0, 1) | 6.77 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 10.55 ± NA |
| DDI Day 1: 2 hr post-dose (n=1,0,0,0,0.0,1) | 8.74 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 10.17 ± NA |
| DDI Day 1: 4 hr post-dose ((n=1,0,0,0,0,0,1) | 6.10 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 6.50 ± NA |
| DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1) | 7.42 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 9.36 ± NA |
| DDI Day 1: 24 hr post-dose (n=1,0,0,0,0,0,0) | 10.84 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| DDI Day 2: 24 hr post-dose ((n= 0,0,0,0,0,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 8.32 ± NA |
| DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1) | 9.46 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 8.94 ± NA |
| DDI Day 3: 2 hr post-dose (n=1,0,0,0,0,0,1) | 3.12 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 15.82 ± NA |
| DDI Day 3: 4 hr post-dose (n-1,0,0,0,0,0,1) | 6.74 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 0.68 ± NA |
| DDI Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1) | 0.81 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 15.68 ± NA |
| DDI Day 3: 24 hr post-dose (n=1,0,0,0,0,0,0) | 6.18 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| DDI Day 4: 24 hr post-dose (n=0,0,0,0,0,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1.06 ± NA |
| C1D1: Pre dose (n=1,1,1,1,1,1,1) | 5.56 ± NA | 3.45 ± NA | 6.96 ± NA | 3.25 ± NA | 3.35 ± NA | 1.97 ± NA | 7.42 ± NA |
| C1D1: 2hr postdose(n= 1,1,1,1,1,1,1) | 2.37 ± NA | 1.33 ± NA | 2.78 ± NA | 1.54 ± NA | 1.40 ± NA | 0.95 ± NA | 1.04 ± NA |
| C1D1: 4hr postdose(n= 1,1,1,1,1,1,1) | 2.85 ± NA | 1.37 ± NA | 2.91 ± NA | 1.24 ± NA | 1.96 ± NA | 1.11 ± NA | 1.01 ± NA |
| C1D1: 8hr postdose(n= 1,1,1,1,1,1,1) | 0.67 ± NA | 0.94 ± NA | 3.40 ± NA | 1.96 ± NA | 1.27 ± NA | 1.12 ± NA | 0.82 ± NA |
| C1D1: 24hr postdose(n= 1,1,1,1,0,0,0) | 6.23 ± NA | 2.15 ± NA | 4.59 ± NA | 6.26 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D2: 24hr postdose(n= 0,0,0,0,1,1,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 3.45 ± NA | 1.26 ± NA | 1.05 ± NA |
| C1D15: pre-dose(n= 1,1,1,1,1,0,1) | 3.79 ± NA | 2.26 ± NA | 5.29 ± NA | 1.41 ± NA | 1.93 ± NA | NA ± NA | 2.03 ± NA |
| C1D15: 2hr postdose (n= 1,1,1,1,1,0,1) | 2.16 ± NA | 1.34 ± NA | 2.83 ± NA | 1.60 ± NA | 1.55 ± NA | NA ± NA | 0.94 ± NA |
| C1D15: 4hr postdose (n= 1,1,1,1,1,0,1) | 1.87 ± NA | 1.34 ± NA | 2.50 ± NA | 0.94 ± NA | 1.20 ± NA | NA ± NA | 0.81 ± NA |
| C1D15: 8hr postdose (n= 1,1,1,1,1,0,1) | 1.92 ± NA | 2.08 ± NA | 3.38 ± NA | 1.10 ± NA | 1.74 ± NA | NA ± NA | 0.99 ± NA |
| C1D15: 24hr postdose (n= 1,1,1,1,0,0,0) | 4.97 ± NA | 0.94 ± NA | 5.33 ± NA | 4.70 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D16: 24hr postdose (n= 0,0,0,0,1,0,1) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2.36 ± NA | NA ± NA | 0.99 ± NA |
| C1D19: pre-dose (n= 1,1,1,1,1,0,1) | 6.54 ± NA | 2.61 ± NA | 4.47 ± NA | 5.44 ± NA | 2.07 ± NA | NA ± NA | 5.72 ± NA |
| C1D19: 2hr postdose (n= 1,0,0,0,0,0,0) | 1.60 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| subjects | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stable disease | 3 | 2 | 2 | 3 | 1 | 2 | 4 | 6 | 0 | 1 | 2 | 7 | 10 | 1 | 7 |
| Progressive disease | 0 | 0 | 1 | 1 | 1 | 0 | 9 | 3 | 2 | 0 | 1 | 8 | 6 | 9 | 4 |
| Complete Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Partial Response | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Evaluable | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 |
Collected over Baseline up to 30 Days after last dose; assessed up to 4 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once Daily | — | 1/3 (33.3%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once Daily | — | 0/3 (0%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once Daily | — | 2/3 (66.7%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once Daily | — | 1/4 (25%) | 4/4 (100%) |
| MSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once Daily | — | 1/4 (25%) | 4/4 (100%) |
| MSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once Daily | — | 1/3 (33.3%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once Daily | — | 14/19 (73.7%) | 19/19 (100%) |
| MSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once Daily | — | 10/14 (71.4%) | 14/14 (100%) |
| MSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once Daily | — | 1/3 (33.3%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice Daily | — | 2/3 (66.7%) | 3/3 (100%) |
| MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily | — | 3/4 (75%) | 4/4 (100%) |
| TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | — | 16/26 (61.5%) | 26/26 (100%) |
| NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | — | 13/24 (54.2%) | 24/24 (100%) |
| CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | — | 10/18 (55.6%) | 18/18 (100%) |
| MEL: Pimasertib 60mg and SAR245409 70mg Once Daily | — | 8/15 (53.3%) | 15/15 (100%) |
| Event | MSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once Daily | MSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice Daily | MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/19 | 0/14 | 0/3 | 0/3 | 2/4 | 0/26 | 0/24 | 2/18 | 0/15 |
| DISEASE PROGRESSIONGeneral disorders | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 4/19 | 1/14 | 0/3 | 0/3 | 2/4 | 1/26 | 3/24 | 2/18 | 0/15 |
| NAUSEAGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/19 | 1/14 | 1/3 | 0/3 | 1/4 | 0/26 | 1/24 | 2/18 | 0/15 |
| VOMITINGGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/19 | 0/14 | 1/3 | 0/3 | 1/4 | 0/26 | 0/24 | 2/18 | 1/15 |
| DYSPHAGIAGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/4 | 0/4 | 0/3 | 0/19 | 0/14 | 0/3 | 0/3 | 0/4 | 0/26 | 1/24 | 0/18 | 0/15 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 1/3 | 0/19 | 0/14 | 0/3 | 0/3 | 1/4 | 0/26 | 0/24 | 0/18 | 0/15 |
| PYREXIAGeneral disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 4/19 | 3/14 | 0/3 | 1/3 | 1/4 | 2/26 | 1/24 | 2/18 | 0/15 |
| CELLULITISInfections and infestations | 0/3 | 0/3 | 1/3 | 0/4 | 0/4 | 0/3 | 0/19 | 0/14 | 0/3 | 0/3 | 0/4 | 1/26 | 0/24 | 0/18 | 1/15 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/19 | 1/14 | 1/3 | 0/3 | 0/4 | 1/26 | 0/24 | 1/18 | 0/15 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 0/3 | 0/3 | 1/3 | 0/4 | 0/4 | 0/3 | 0/19 | 0/14 | 0/3 | 0/3 | 0/4 | 0/26 | 0/24 | 0/18 | 0/15 |
| Event | MSC1936369B (Pimasertib) 15mg and SAR245409 30mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 30mg Once Daily | MSC1936369B (Pimasertib) 15mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 50mg Once Daily | MSC1936369B (Pimasertib) 30mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 90mg and SAR245409 70mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 90mg Once Daily | MSC1936369B (Pimasertib) 60mg and SAR245409 30mg Twice Daily | MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 3/3 | 2/3 | 2/3 | 4/4 | 2/4 | 2/3 | 10/19 | 13/14 | 1/3 | 3/3 | 1/4 | 22/26 | 19/24 | 13/18 | 10/15 |
| NAUSEAGastrointestinal disorders | 1/3 | 2/3 | 2/3 | 1/4 | 1/4 | 3/3 | 7/19 | 8/14 | 2/3 | 3/3 | 0/4 | 11/26 | 15/24 | 8/18 | 7/15 |
| VOMITINGGastrointestinal disorders | 1/3 | 1/3 | 0/3 | 0/4 | 2/4 | 3/3 | 8/19 | 9/14 | 1/3 | 2/3 | 3/4 | 12/26 | 11/24 | 7/18 | 8/15 |
| FATIGUEGeneral disorders | 3/3 | 1/3 | 2/3 | 2/4 | 3/4 | 2/3 | 8/19 | 9/14 | 2/3 | 3/3 | 4/4 | 17/26 | 14/24 | 9/18 | 4/15 |
| OEDEMA PERIPHERALGeneral disorders | 1/3 | 2/3 | 3/3 | 1/4 | 1/4 | 0/3 | 7/19 | 7/14 | 1/3 | 2/3 | 1/4 | 7/26 | 5/24 | 3/18 | 4/15 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 3/3 | 2/3 | 0/3 | 2/4 | 0/4 | 2/3 | 9/19 | 6/14 | 1/3 | 2/3 | 1/4 | 13/26 | 8/24 | 4/18 | 7/15 |
| HYPERTENSIONSkin and subcutaneous tissue disorders | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 3/19 | 0/14 | 3/3 | 0/3 | 1/4 | 3/26 | 3/24 | 1/18 | 5/15 |
| COUGHRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/3 | 1/4 | 3/4 | 0/3 | 1/19 | 2/14 | 0/3 | 1/3 | 0/4 | 3/26 | 4/24 | 2/18 | 1/15 |
| RASH MACULO-PAPULARSkin and subcutaneous tissue disorders | 1/3 | 1/3 | 0/3 | 2/4 | 3/4 | 0/3 | 6/19 | 5/14 | 1/3 | 2/3 | 3/4 | 6/26 | 12/24 | 4/18 | 5/15 |
| ANAEMIABlood and lymphatic system disorders | 1/3 | 0/3 | 2/3 | 1/4 | 1/4 | 0/3 | 7/19 | 3/14 | 1/3 | 0/3 | 0/4 | 4/26 | 2/24 | 4/18 | 0/15 |
The Safety analysis set (SAF) included subjects who received at least one (non-zero) administration of the trial IMPs (pimasertib and/or SAR245409).
| Age, Categorical(Participants) | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 1 | 2 | 1 | 2 | 16 | 12 | 3 | 2 | 2 | 22 | 16 | 12 | 13 | 107 |
| >=65 years | 1 | 2 | 2 | 2 | 3 | 1 | 3 | 2 | 0 | 1 | 2 | 4 | 8 | 6 | 2 | 39 |
| Gender(Participants) | Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily | Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily | Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily | Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily | Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily | TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily | NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily | CRC: Pimasertib 60mg and SAR245409 70mg Once Daily | MEL: Pimasertib 60mg and SAR245409 70mg Once Daily | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 2 | 1 | 1 | 1 | 6 | 13 | 1 | 2 | 0 | 26 | 15 | 11 | 4 | 87 |
| Male | 0 | 2 | 1 | 3 | 3 | 2 | 13 | 1 | 2 | 1 | 4 | 0 | 9 | 7 | 11 | 59 |
The record gives a start of May 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pimasertib · XL765